Johnson & Johnson coronavirus vaccine shows response in 98% of test participants

One of the numerous proposed coronavirus vaccines has produced a strong immune response in test subjects according to a report issued Friday.

Johnson & Johnson's JNJ.N Covid-19 vaccine, called Ad26.COV2.S, was well-tolerated by subjects at two dosing instances in early-to-mid stage coronavirus clinical trials.

It is the only Phase 3 Covid-19 vaccine trial in the US that is testing a single dose vaccine.

Researchers said 98 per cent of participants in the study whose data was available had neutralising antibodies, which help the body fight off pathogens, a month after they received the vaccine.